Advertisement
Screener

MAIA Biotechnology, Inc. (MAIA) Operating Cash Flow

2.8 / 5 stars · 68/120 Roast Me

MAIA Biotechnology, Inc. Operating Cash Flow

MAIA Biotechnology, Inc. (MAIA) reported Operating Cash Flow of -$12.06 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.

Financial Statements › Cash Flow › Operating Activities

us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-10

  • MAIA Biotechnology, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$6.75M.
  • MAIA Biotechnology, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$5.31M.
  • MAIA Biotechnology, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$7.02M.
  • MAIA Biotechnology, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$3.49M.
  • MAIA Biotechnology, Inc. net cash provided by (used in) operating activities for fiscal 2025 was -$18.84M.
  • MAIA Biotechnology, Inc. net cash provided by (used in) operating activities for fiscal 2024 was -$15.70M.
  • MAIA Biotechnology, Inc. net cash provided by (used in) operating activities for fiscal 2023 was -$13.07M.
  • MAIA Biotechnology, Inc. net cash provided by (used in) operating activities for fiscal 2022 was -$12.10M.
Period endNet Cash Provided by (Used in) Operating Activities 3 monthNet Cash Provided by (Used in) Operating Activities 6 monthNet Cash Provided by (Used in) Operating Activities 9 monthNet Cash Provided by (Used in) Operating Activities 12 monthNet Cash Provided by (Used in) Operating Activities 12 month as first filed
2026-06-30-$6.75M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10
-$12.06M
10-Q · filed 2026-08-10
-$19.08M
derived: sum of 3 quarters · filed 2026-08-10
-$22.57M
derived: sum of 4 quarters · filed 2026-08-10
2026-03-31-$5.31M
10-Q · filed 2026-05-11
-$12.33M
derived: sum of 2 quarters · filed 2026-05-11
-$15.82M
derived: sum of 3 quarters · filed 2026-05-11
-$19.95M
derived: sum of 4 quarters · filed 2026-08-10
2025-12-31-$7.02M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23
-$10.51M
derived: sum of 2 quarters · filed 2026-03-23
-$14.64M
derived: sum of 3 quarters · filed 2026-08-10
-$18.84M
10-K · filed 2026-03-23
2025-09-30-$3.49M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07
-$7.62M
derived: sum of 2 quarters · filed 2026-08-10
-$11.82M
10-Q · filed 2025-11-07
-$15.73M
derived: sum of 4 quarters · filed 2026-08-10
2025-06-30-$4.14M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10
-$8.34M
10-Q · filed 2026-08-10
-$12.25M
derived: sum of 3 quarters · filed 2026-08-10
-$15.77M
derived: sum of 4 quarters · filed 2026-08-10
2025-03-31-$4.20M
10-Q · filed 2026-05-11
-$8.11M
derived: sum of 2 quarters · filed 2026-05-11
-$11.64M
derived: sum of 3 quarters · filed 2026-05-11
-$16.32M
derived: sum of 4 quarters · filed 2026-05-11
2024-12-31-$3.91M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23
-$7.43M
derived: sum of 2 quarters · filed 2026-03-23
-$12.12M
derived: sum of 3 quarters · filed 2026-03-23
-$15.70M
10-K · filed 2026-03-23
2024-09-30-$3.52M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07
-$8.21M
derived: sum of 2 quarters · filed 2025-11-07
-$11.80M
10-Q · filed 2025-11-07
-$15.79M
derived: sum of 4 quarters · filed 2025-11-07
2024-06-30-$4.68M
derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11
-$8.27M
10-Q · filed 2025-08-11
-$12.26M
derived: sum of 3 quarters · filed 2025-08-11
-$15.42M
derived: sum of 4 quarters · filed 2025-08-11
2024-03-31-$3.59M
10-Q · filed 2025-05-09
-$7.58M
derived: sum of 2 quarters · filed 2025-05-09
-$10.74M
derived: sum of 3 quarters · filed 2025-05-09
-$13.30M
derived: sum of 4 quarters · filed 2025-05-09
2023-12-31-$3.99M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-21
-$7.15M
derived: sum of 2 quarters · filed 2025-03-21
-$9.71M
derived: sum of 3 quarters · filed 2025-03-21
-$13.07M
10-K · filed 2025-03-21
2023-09-30-$3.16M
derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12
-$5.72M
derived: sum of 2 quarters · filed 2024-11-12
-$9.08M
10-Q · filed 2024-11-12
-$12.03M
derived: sum of 4 quarters · filed 2024-11-12
2023-06-30-$2.56M
derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-09
-$5.92M
10-Q · filed 2024-08-09
-$8.87M
derived: sum of 3 quarters · filed 2024-08-09
-$13.19M
derived: sum of 4 quarters · filed 2024-08-09
2023-03-31-$3.36M
10-Q · filed 2024-05-14
-$6.31M
derived: sum of 2 quarters · filed 2024-05-14
-$10.63M
derived: sum of 3 quarters · filed 2024-05-14
-$12.65M
derived: sum of 4 quarters · filed 2024-05-14
2022-12-31-$2.95M
derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21
-$7.27M
derived: sum of 2 quarters · filed 2024-03-21
-$9.29M
derived: sum of 3 quarters · filed 2024-03-21
-$12.10M
10-K · filed 2024-03-21
-$11.66M
10-K · filed 2023-03-24
2022-09-30-$4.32M
derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07
-$6.34M
derived: sum of 2 quarters · filed 2023-11-07
-$9.15M
10-Q · filed 2023-11-07
-$10.75M
derived: sum of 4 quarters · filed 2023-11-07
2022-06-30-$2.02M
derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08
-$4.83M
10-Q · filed 2023-08-08
-$6.43M
derived: sum of 3 quarters · filed 2023-08-08
-$7.75M
derived: sum of 4 quarters · filed 2023-08-08
2022-03-31-$2.81M
10-Q · filed 2023-05-08
-$4.42M
derived: sum of 2 quarters · filed 2023-05-08
-$5.73M
derived: sum of 3 quarters · filed 2023-05-08
2021-12-31-$1.61M
derived: 10-K 12 month − 10-Q/A 9 month · filed 2023-03-24
-$2.92M
derived: sum of 2 quarters · filed 2023-03-24
-$4.12M
10-K · filed 2023-03-24
2021-09-30-$1.31M
derived: 10-Q/A 9 month − 10-Q 6 month · filed 2023-02-06
-$2.52M
10-Q/A · filed 2023-02-06
2021-06-30-$1.20M
10-Q · filed 2022-08-22

Similar stocks

Stock NameCountryMarket CapPE Ratio
iBio, Inc. (IBIO)United States$0.077B-2.94
Valion Bio, Inc. (VBIO)United States$0.077B
Adicet Bio, Inc. (ACET)United States$0.078B-0.81
Lifevantage Corp (LFVN)United States$0.078B15.40
Verrica Pharmaceuticals Inc. (VRCA)United States$0.076B-3.39
OS Therapies Inc (OSTX)United States$0.076B-2.17
Gain Therapeutics, Inc. (GANX)United States$0.080B-4.40
Aldeyra Therapeutics, Inc. (ALDX)United States$0.074B-5.57
Cingulate Inc. (CING)United States$0.073B-2.64
Spero Therapeutics, Inc. (SPRO)United States$0.073B17.41